GLP-1 medicines and brain health: real-world clues about dementia risk
Official title: A GLIMMER of possibility? GLucagon-like Peptide-1 Receptor Agonists—Investigating their Influence on the Mind, Metabolism, and Early Risk for ADRDs in the Understanding America Study
Funded at University of Southern California · NIH-11607813 · Data updated 2026-11-12
A nationwide study will follow adults 21 and older using GLP-1 medicines to see how these drugs relate to memory, thinking, and dementia risk in real life.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project start | September 15, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $6,073,092 |
| NIH project number | 1R56AG101713-01 |
| Project ID | NIH-11607813 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults 21+ who are using or considering GLP-1 receptor agonist therapy and are enrolled in the Understanding America Study or willing to participate in additional surveys and phenotyping.
✕Less likely to help
Patients not using GLP-1 therapies or not participating in the UAS-derived data streams may have limited direct relevance to the study findings.
What this research studies
GLIMMER will embed a real-world GLP surveillance platform in the Understanding America Study, tracking GLP-1 receptor agonist use every month and collecting annual surveys and deep phenotyping data from consenting participants. The study aims to capture treatment dynamics, cognitive and metabolic changes, and lifestyle factors to better understand how GLP-1 therapies relate to dementia risk outside traditional clinical trials. Participants will contribute information from diverse sources, including body composition, glucose monitoring, and daily dietary context, to build a comprehensive picture of real-world effects. This approach prioritizes timely data and broad representation to inform future research and care for people at risk for Alzheimer's disease and related dementias.
Why it matters
Potential benefit: If successful, this work could clarify how GLP-1 therapies influence brain health in everyday settings and guide future prevention strategies for dementia.
How similar studies have gone: Real-world pharmacovigilance and observational data platforms have yielded important insights, but this study uniquely links GLP-1 use with deep, real-time phenotyping in a nationally representative sample.
Where this research is happening
-
University of Southern California
Los Angeles, United States Active
Researchers
- Principal investigator: Gracner, Tadeja — University of Southern California
- Study coordinator: Gracner, Tadeja
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.